CD274 and neoplasm: Currently, biomarkers for predicting the efficacy of ICIs mainly include PD-L1, tumor mutational burden (TMB), microsatellite instability (MSI), and gene expression profile of tumor-infiltrating lymphocytes (TILs) (11).